Immune-based detection of rifampicin-resistance in HIV/TB
Immune-based detection of rifampicin-resistance in HIV/TB
批准号:
8603454
负责人:
GREGORY P. BISSON
金额:
$17.77万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2015-06-30
关键词:
AdultAfrica South of the SaharaAnimal ModelAntibiotic ResistanceAntigensAreaBacillus subtilisBiological AssayBotswanaCessation of lifeClinicalCollectionCommunicable DiseasesCountryDataDetectionDiseaseDrug Resistant TuberculosisDrug resistanceDrug resistance in tuberculosisEpidemicEpidemiologyEvaluationExtreme drug resistant tuberculosisGene ActivationGene MutationGenesHIVHIV InfectionsHigh PrevalenceHumanImmuneImmune responseImmune systemImmunology procedureIncidenceIndividualInfectionLeadMemoryMethodsMicrobiologyMulti-Drug ResistanceMultidrug-Resistant TuberculosisMutationMycobacterium tuberculosisMycobacterium tuberculosis antigensOrganismPatientsPharmaceutical PreparationsPopulations at RiskPredispositionPrevalenceProteinsProteomeProteomicsPublic HealthPublishingPulmonary TuberculosisReportingResearchResistanceRifampicin resistanceRifampinRiskSamplingSelection for TreatmentsSingle Nucleotide PolymorphismSouthern AfricaSpecimenStreptomyces lividansTimeTime StudyTuberculosisbaseblindclinical caredata modelinghigh riskimmune functionimprovedinnovationisoniazidlatent infectionmortalitymutantnovelpathogenpublic health emergencypublic health relevanceresearch studyresistant strain
中文摘要
描述(由申请人提供):近20亿人,即世界人口的三分之一,处于活动性结核病(TB)的风险中,因为他们潜伏地感染了病原体结核分枝杆菌(Mtb),并且每年发生近200万例与TB相关的死亡。艾滋病毒增加了结核病的风险,耐多药结核病(MDR-TB),定义为对异烟肼(INH)和利福平耐药的结核病,已成为撒哈拉以南非洲一些地区的公共卫生紧急情况,那里的艾滋病毒流行率和结核病发病率是世界上最高的。结核病控制的一个主要障碍是,检测结核分枝杆菌耐药性需要收集微生物样本,而在许多艾滋病毒活动性疾病病例和所有潜伏感染病例中,这是不可能的。事实上,如果怀疑存在耐药性,则不能适当地靶向治疗潜伏感染,这是全球消除结核病的必要方法,重要的是,耐药性潜伏结核病感染的范围是未知的。微生物学和传染病的一个中心原则是,鉴定人类病原体的抗生素耐药性需要直接接触生物体。我们的总体假设通过假设病原体的蛋白质组中的变化(其特异性地作为赋予耐药性的基因突变的结果而发生)可以通过宿主适应性免疫系统进行免疫学检测来挑战这种范式。该假说有两个部分:1)某些基因被耐药菌株特异性上调,2)这些基因的产物可以被宿主适应性免疫系统识别。我们最近发表的蛋白质组学实验已经确定了许多特定的蛋白质,这些蛋白质在rpoB中具有单核苷酸多态性(SNP)的Mtb菌株中上调或特异性表达,这些Mtb菌株赋予对利福平的耐药性,如果存在于临床疾病中,通常表明MDR-TB。此外,特异性基因激活利福平耐药,rpoB突变Mtb是一致的模式生物,包括枯草芽孢杆菌和变铅青链霉菌的数据,在rpoB突变可以显着激活休眠基因网络不表达的野生型菌株。在本提案中,我们将分析博茨瓦纳艾滋病毒感染者和未感染者对先前确定的候选“利福平耐药抗原”的细胞免疫反应,其中艾滋病毒的流行率接近20%。具体而言,我们将前瞻性地比较利福平耐药与利福平敏感肺结核个体对一组新抗原的记忆免疫应答,因为感染结核分枝杆菌分离株的潜在药物敏感性可以在活动性疾病中确定。这项概念验证研究代表了重要的第一步,以评估一种创新的间接方法来确定结核分枝杆菌的药物敏感性,特别是在潜伏感染期间,目前无法评估耐药性。通过这样做,该提案有可能通过首次允许对耐药潜伏感染的流行病学进行研究来改善结核病临床护理,最重要的是,从根本上改变了全球结核病控制的公共卫生方法。
英文摘要
DESCRIPTION (provided by applicant): Nearly 2 billion people, one third of the World's population, are at risk of active tuberculosis (TB) because they are latently infected with the causative agent Mycobacterium tuberculosis (Mtb), and almost 2 million TB- related deaths occur annually. HIV increases the risk of TB, and multi-drug resistant TB (MDR-TB), defined as TB resistant to both isoniazid (INH) and rifampicin, has become a public health emergency in some parts of sub-Saharan Africa, where the HIV prevalence and TB incidence rates are the highest in the world. A major barrier to TB control is that detection of Mtb drug resistance requires collection of microbiological samples, which are not available in many cases of active disease in HIV and in all cases of latent infection. Indeed, treatment of latent infection, a necessary approach to global TB elimination, cannot be properly targeted if drug resistance is suspected and, importantly, the scope of drug-resistant latent Mtb infection is unknown. A central tenet of microbiology and infectious diseases holds that identification of antibiotic resistance in human pathogens requires direct access to the organism. Our overarching hypothesis challenges this paradigm by hypothesizing that the changes in the proteome of pathogens that specifically occur as a result of genetic mutation(s) conferring drug resistance can be immunologically detected by the host adaptive immune system. This hypothesis has two parts - 1) that certain genes are specifically upregulated by drug resistant strains, and 2) that te products of these genes can be recognized by the host adaptive immune system. Our recently published proteomics experiments have identified numerous specific proteins that are either upregulated in or specifically expressed by Mtb strains that have single nucleotide polymorphisms (SNPs) in rpoB conferring resistance to rifampicin, which, if present in clinical disease, usually indicates MDR-TB. Furthermore, specific gene activation by rifampicin-resistant, rpoB-mutant Mtb is consistent with data from model organisms, including Bacillus subtilis and Streptomyces lividans, in that rpoB mutation can dramatically activate dormant gene networks not expressed by wild-type strains. In this proposal, we will analyze cellular immune responses to previously identified candidate "rifampicin-resistance antigens" in HIV- infected and uninfected adults in Botswana, where the prevalence of HIV is nearly 20%. Specifically, we will prospectively compare memory immune responses to a panel of novel antigens in individuals with rifampicin- resistant versus rifampicin-susceptible pulmonary TB, as the underlying drug-susceptibility of the infecting Mtb isolates can be determined in active disease. This proof-of-concept study represents an important first step to evaluating an innovative, indirect method to determine drug susceptibility in Mtb, particularly during latent infection, wher drug resistance currently cannot be assessed. By so doing, this proposal has the potential to improve TB clinical care by allowing, for the first time, study of the epidemiology of drug-resistant latent infection and, most importantly, radically transforming public health approaches to global TB control.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Gleevec for TB and TB/HIV
-
批准号:9150519
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2015
-
负责人:GREGORY P. BISSON
-
依托单位:
Development of Gleevec for TB and TB/HIV
-
批准号:9040684
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2015
-
负责人:GREGORY P. BISSON
-
依托单位:
Development of Gleevec for TB and TB/HIV
-
批准号:9761965
-
项目类别:
-
资助金额:$157.12万
-
财政年份:2015
-
负责人:GREGORY P. BISSON
-
依托单位:
Rapid Immune Restoration and Lung Injury in HIV/TB
-
批准号:9063095
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2015
-
负责人:GREGORY P. BISSON
-
依托单位:
Immune Activation and Isoniazid Metabolism in HIV/TB
-
批准号:8660284
-
项目类别:
-
资助金额:$20.65万
-
财政年份:2013
-
负责人:GREGORY P. BISSON
-
依托单位:
Immune-based detection of rifampicin-resistance in HIV/TB
-
批准号:8685124
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2013
-
负责人:GREGORY P. BISSON
-
依托单位:
Immune Activation and Isoniazid Metabolism in HIV/TB
-
批准号:8467862
-
项目类别:
-
资助金额:$24.63万
-
财政年份:2013
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:8041155
-
项目类别:
-
资助金额:$16.24万
-
财政年份:2010
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:7621283
-
项目类别:
-
资助金额:$74.16万
-
财政年份:2009
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:7744630
-
项目类别:
-
资助金额:$67.65万
-
财政年份:2009
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:8499572
-
项目类别:
-
资助金额:$4.14万
-
财政年份:2009
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:8213470
-
项目类别:
-
资助金额:$97.56万
-
财政年份:2009
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:8016040
-
项目类别:
-
资助金额:$77.14万
-
财政年份:2009
-
负责人:GREGORY P. BISSON
-
依托单位:
Immunology and Outcomes after HAART in HIV/TB Coinfection
-
批准号:8440788
-
项目类别:
-
资助金额:$17.57万
-
财政年份:2009
-
负责人:GREGORY P. BISSON
-
依托单位:
Effect of GBV-C on HIV
-
批准号:6866458
-
项目类别:
-
资助金额:$13.25万
-
财政年份:2004
-
负责人:GREGORY P. BISSON
-
依托单位:
Effect of GBV-C on HIV
-
批准号:6746503
-
项目类别:
-
资助金额:$13.25万
-
财政年份:2004
-
负责人:GREGORY P. BISSON
-
依托单位:
Effect of GBV-C on HIV
-
批准号:7356466
-
项目类别:
-
资助金额:$13.25万
-
财政年份:2004
-
负责人:GREGORY P. BISSON
-
依托单位:
Effect of GBV-C on HIV
-
批准号:7039034
-
项目类别:
-
资助金额:$13.25万
-
财政年份:2004
-
负责人:GREGORY P. BISSON
-
依托单位:
海外基金